The prices of ten of the most expensive and widely used prescription drugs in the USA are to be capped from 2026, under a deal reached by drug manufacturers and US President Joe Biden’s administration, which was negotiating for the first time on behalf of Medicare, the public health insurance programme for people aged 65 years or older and for younger people with disabilities, including those with end stage renal disease and amyotrophic lateral sclerosis.